{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:16:43Z","timestamp":1793236603042,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03950-w","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:50:44Z","timestamp":1749822644000},"page":"4481-4492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study)"],"prefix":"10.1007","volume":"27","author":[{"given":"Marta","family":"Sotelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Pelaez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Basterretxea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrella","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"S\u00e1nchez-Escribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Pujol Obis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Santander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Mart\u00ednez Kareaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Arruti Ibarbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Rodr\u00edguez Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"\u00c1lvarez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Piedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Calderero Arag\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lainez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Verd\u00fan Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gil Arn\u00e1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mazas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9053-3763","authenticated-orcid":false,"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"3","key":"3950_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA: A Cancer J Clin"},{"issue":"8","key":"3950_CR2","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters A, Aben KK, Kiemeney LA. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895\u2013904.","journal-title":"World J Urol"},{"key":"3950_CR3","unstructured":"Las cifras del c\u00e1ncer en Espana 2024. Accessed 25 Oct 2024. https:\/\/seom.org\/git-en\/150025-seom\/210347-las-cifras-del-cancer-dia-mundial-2024"},{"key":"3950_CR4","unstructured":"Network NCC. Clinical practical guidelines in oncology: bladder cancer, version 3. 2020. Accessed 12 Sept 2024. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/bladder.pdf"},{"issue":"10","key":"3950_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","volume":"30","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, et al. Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30(10):1107\u201313.","journal-title":"J Clin Oncol"},{"key":"3950_CR6","doi-asserted-by":"publisher","first-page":"5682078","DOI":"10.1155\/2018\/5682078","volume":"2018","author":"N Bukhari","year":"2018","unstructured":"Bukhari N, Al-Shamsi HO, Azam F. Update on the treatment of metastatic urothelial carcinoma. Sci World J. 2018;2018:5682078.","journal-title":"Sci World J"},{"key":"3950_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, Matsubara N, G\u00e9czi L, Cheng SY, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:931\u201345.","journal-title":"Lancet Oncol"},{"key":"3950_CR8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arija J\u00c1A, Bamias A, Davis ID, De Santis M, Kikuchi E, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1547\u201357.","journal-title":"Lancet"},{"issue":"5","key":"3950_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11523-019-00665-1","volume":"14","author":"P Grivas","year":"2019","unstructured":"Grivas P, Monk BJ, Petrylak D, Reck M, Foley G, Guenther S, et al. Immune checkpoint inhibitors as switch or continuation maintenance therapy in solid tumors: rationale and current state. Target Oncol. 2019;14(5):505\u201325.","journal-title":"Target Oncol"},{"issue":"4","key":"3950_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/cpt.986","volume":"103","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Narwal R, Jin C, Baverel PG, Jin X, Gupta A, et al. Population modeling of tumor kinetics and overall survival to identify prognostic and predictive biomarkers of efficacy for durvalumab in patients with urothelial carcinoma. Clin Pharmacol Ther. 2018;103(4):643\u201352.","journal-title":"Clin Pharmacol Ther"},{"key":"3950_CR11","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218\u201330.","journal-title":"N Engl J Med"},{"key":"3950_CR12","unstructured":"FDA approves avelumab for urothelial carcinoma maintenance treatment. Accessed 17 Sept 2024. Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fdaapproves-avelumab-urothelial-carcinoma-maintenance-treatment#:~:text=On%20June%2030%2C%202020% 2C%20the,%2Dline%20platinum%2Dcontaining%20chemotherapy"},{"key":"3950_CR13","unstructured":"European Commission Approves BAVENCIO\u00ae (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma. Accessed 17 Sept 17 2024. Available at: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/european-commission-approves-bavencior-avelumab-first-line."},{"issue":"19","key":"3950_CR14","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.22.01792","volume":"41","author":"T Powles","year":"2023","unstructured":"Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ull\u00e9n A, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up. J Clin Oncol. 2023;41(19):3486\u201392.","journal-title":"J Clin Oncol"},{"key":"3950_CR15","unstructured":"FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer. Accessed 17 Sept 2024. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer"},{"key":"3950_CR16","unstructured":"European Commission Approves Astellas' PADCEV\u2122 (enfortumab vedotin) in Combination with KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer. Accessed 17 Sept 2024. Available at: https:\/\/www.prnewswire.com\/news-releases\/european-commission-approves-astellas-padcev-enfortumab-vedotin-in-combination-with-keytruda-pembrolizumab-for-first-line-treatment-of-advanced-urothelial-cancer-302232067.html"},{"issue":"19","key":"3950_CR17","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, CheckMate 901 Trial Investigators, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2309863.","journal-title":"N Engl J Med"},{"key":"3950_CR18","unstructured":"FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma. Accessed 17 Sept 2024. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-combination-cisplatin-and-gemcitabine-unresectable-or-metastatic-urothelial#:~:text=On%20March%206%2C%202024%2C%20the,metastatic%20urothelial%20carcinoma%20(UC)."},{"issue":"Suppl_6","key":"3950_CR19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1200\/JCO.2023.41.6_suppl.508","volume":"41","author":"SS Sridhar","year":"2023","unstructured":"Sridhar SS, Powles T, Gupta S, Climent MA, Aragon-Ching JB, Sternberget CN, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy. J Clin Oncol. 2023;41(Suppl_6):508.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3950_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.eururo.2023.08.001","volume":"85","author":"SS Sridhar","year":"2024","unstructured":"Sridhar SS, Powles T, Climent Dur\u00e1n M\u00c1, Park SH, Massari F, Thiery-Vuillemin A, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: analysis from JAVELIN bladder 100 by duration of first-line chemotherapy and interval before maintenance. Eur Urol. 2024;85(2):154\u201363.","journal-title":"Eur Urol"},{"issue":"suppl 6","key":"3950_CR21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/JCO.2023.41.6_suppl.471","volume":"41","author":"P Barthelemy","year":"2023","unstructured":"Barthelemy P, Loriot Y, Voog E, Eymard JC, Ravaud A, Flechon A, et al. Full analysis from AVENANCE: a real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC). J Clin Oncol. 2023;41(suppl 6):471.","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"3950_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2023.41.6_suppl.469","volume":"41","author":"L Antonuzzo","year":"2023","unstructured":"Antonuzzo L, Maruzzo M, De Giorgi U, Santini D, Tambaro R, Buti S, et al. READY: real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la\/mUC). J Clin Oncol. 2023;41(suppl 6):469.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3950_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.clgc.2023.06.008","volume":"21","author":"DR Bakaloudi","year":"2023","unstructured":"Bakaloudi DR, Talukder R, Lin GI, Makrakis D, Diamantopoulos LN, Tripathi N, et al. Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC): \u201creal world\u201d experience. Clin Genitourin Cancer. 2023;21(5):584\u201393.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"3950_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000538237","volume":"108","author":"S Banek","year":"2024","unstructured":"Banek S, Wenzel M, Lauer B, Le QC, Hoeh B, Koll F, et al. Real-world evidence of tumor and patient characteristics and survival with avelumab maintenance after chemotherapy for advanced and metastatic urothelial carcinoma. Urol Int. 2024;108(4):285\u201391.","journal-title":"Urol Int"},{"issue":"8","key":"3950_CR25","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/iju.15473","volume":"31","author":"E Kikuchi","year":"2024","unstructured":"Kikuchi E, Hayakawa N, Nakayama M, Uno M, Nakatsu H, Kitagawa C, et al. J-AVENUE: a retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan. Int J Urol. 2024;31(8):859\u201367.","journal-title":"Int J Urol"},{"key":"3950_CR26","doi-asserted-by":"publisher","first-page":"1403120","DOI":"10.3389\/fonc.2024.1403120","volume":"14","author":"SH Park","year":"2024","unstructured":"Park SH, Shin SJ, Rha SY, Beom SH, Seo HK, Keam B, et al. Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program. Front Oncol. 2024;14:1403120.","journal-title":"Front Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03950-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03950-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03950-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:29:05Z","timestamp":1763562545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03950-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3950"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03950-w","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Astellas has contributed a grant to support a portion of the program\u2019s cost, but they have not exerted any influence or input on the research program.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board and Ethics Committee of all the participant centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained whenever required by the Spanish Law.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}